

Antibody Response in Korean Raccoon Dogs Inoculated with Inactivated Rabies Vaccines

Dong-Kun Yang^{1*}, Tae-Oh Go², Young-Hee Nam², Ha-Hyun Kim¹, Soo-Dong Cho¹,
Kyung-Woo Lee¹, Sung-Suk Choi¹ and Jae-Young Song¹

¹Animal, Plant and Fisheries Quarantine and Inspection Agency, Anyang, Gyeonggi-do; MFAFF, Republic of Korea,

²Wild Life Center, Gyeonggi-do Veterinary Service Laboratory

Since sylvatic rabies was first identified in South Korea in 1993, over three million bait vaccine doses have been distributed to rabies risk regions in order to block transmission of rabies among wild animals. New progressive strategy is needed to eliminate sylvatic rabies completely in rabies risk regions. Before applying the preventive program related to eradication, immunogenicity of inactivated rabies vaccines available in Korea has to be evaluated in Korean raccoon dogs (*Nyctereutes procyonoides koreensis*). Six groups of raccoon dogs in wild rescue center of Gyeonggi-do were vaccinated intramuscularly with single dose of six inactivated commercial rabies vaccines (designated A to F). Serum samples at the time of vaccination, and two and four weeks post vaccination were obtained and analyzed by virus neutralizing assay (VNA). All raccoon dogs inoculated with vaccines C, D, E or F, showed VN antibody titers ranging from 0.5 to 13.77 IU/ml. Half of four raccoon dogs immunized with vaccine B revealed VN titer over 0.5 IU/ml, and one of four raccoon dogs inoculated with vaccine A showed protective antibody titer. This finding suggests that most of the commercially available inactivated rabies vaccines could induce protective immunity in Korean raccoon dogs and be applicable to new rabies control program.

Key Words: Inactivated vaccine, Immunogenicity, Rabies, Raccoon dog

INTRODUCTION

Rabies is an important zoonosis that occurs in more than 150 nations around the world and is claiming lives of 55,000 people annually (1). Especially, mortality rate is increasing in Africa, Asia and Latin America and some countries need support of other World Animal Health

Organization (OIE) members that successfully eradicated the disease. Since the first rabies case in dogs in 1907, a number of rabies cases in Korea have been reported in several animal species such as dogs, cattle, raccoon dogs and cats at several provinces until 2011 (2, 3). As the result of the implement of Korean government's policy including intensive vaccination to dogs with live attenuated rabies vaccine (LEP Fulry and ERA strain), removal of stray dogs and carrying out rabies awareness campaigns continuously, a steady decrease in the number of animal rabies cases was observed in period between 1960 and 1984 and no rabies case was reported for 8 years from 1985 to 1992 (2~4).

Rabies is transmitted by several kinds of vectors including dogs, bats, raccoon dogs, red foxes, wolves and mongooses depending on the national situation (5~7). Dogs were

Received: May 25, 2012/ Revised: August 14, 2012

Accepted: August 20, 2012

*Corresponding author: Dong-Kun Yang. Animal, Plant and Fisheries Quarantine and Inspection Agency, 175 Anyang-ro, Anyang-si, Gyeonggi-do 430-757, Korea.

Phone: +82-31-467-1783, Fax: +82-31-467-1797

e-mail: yangdk@korea.kr

**This work was supported financially by a grant (B-AD14-2011-13-01) from the Animal, Plant and Fisheries Quarantine and Inspection Agency, Ministry for Food, Agriculture, Forestry and Fisheries, Korea.

known to be the main vector for the transmission of rabies virus (RABV) to human or other animals in Korea prior to 1984. Unfortunately, a recurrence of the rabies in dog fighting with rabid raccoon dog was identified in Gangwon-do Province in 1993 and a continuous increase of rabies cases was observed. The epidemiological study on rabies reported that wild animals such as raccoon dogs (*Nyctereutes procyonoides koreensis*) and badger (*Meles meles*) played an important role in transmitting rabies to cattle and dogs in Korea (4, 8). Since 1993, dog-to-dog transmission (urban rabies) was eliminated in Korea (2, 3), but sylvatic rabies has been identified up to 2011. In order to block rabies transmission by wild animals such as raccoon dogs, Korean government made a decision to distribute vaccinia-rabies glycoprotein (V-RG) bait vaccine in 2000 after trial application and over three million bait vaccine doses have been distributed to rabies risk provinces by a direct way (Gyeonggi-do, Gangwon-do) (3). As the result of distributing bait vaccine, rabies case has not been reported in Gyeonggi-do Province since 2007. However, it continuously has been occurring and the areas of rabies have moved eastward in Gangwon-do Province (4). Even though oral rabies vaccination (ORV) such as distribution of bait vaccine has been found to be efficacious policy in reducing rabies case, new strategy has been presented to control rabies completely. In addition, previous study reported that vaccination of raccoon (*Procyon lotor*) and skunk with inactivated rabies vaccine elicited good immunogenicity and protected them from challenge with wild RABV (9, 10). Based on the immunogenicity of commercial inactivated vaccine in Canada and USA, new strategies including trap-vaccination-release (TVR), ORV, point infection control (PIC), and population reduction (PR) programs have been applied to several provinces of the countries and made Ontario state of Canada pronounce free of rabies in 2008 (4, 11).

Therefore, the application of new rabies control program to completely eliminate rabies transmitted by raccoon dogs is needed to the rabies risk regions of Korea. Before applying the new preventive program, immunogenicity of inactivated rabies vaccine available in Korea have to be

evaluated in Korean raccoon dogs. The aim of this study was to describe immunogenicity of 6 kinds of commercial inactivated rabies vaccines after vaccination to Korean raccoon dogs and provide preliminary information associated with eradication program in Korea.

MATERIALS AND MTEHODS

Vaccines

The one inactivated rabies vaccine was from Korean animal vaccine company and the other five were purchased from international companies. The six vaccines used in this study were as follows: CaniShot[®] RV-F (ChoongAng Co., Korea), DEFENSOR[®] 3 (Pfizer Animal Health, USA), Nobivac[®] Rabies (Intervet, Netherlands), Rabdomun[®] (Shering-Plough, USA), Rabigen[®] mono (Virbac, France), Rabisin[®] (Merial, France), designating A, B, C, D, E, and F, respectively. They were all licensed to use in Korea for dogs, cats and cattle, but not for raccoon dogs.

Immunization and blood sampling

All trials were conducted in wild animal rescue center located in Gyeonggi-do Province. In brief, each group consisting of four Korean raccoon dogs were inoculated with one dose of each commercial vaccine intramuscularly and control group remained without any vaccination. Bloods were taken from cephalic vein at the beginning of the experiment, and 14 and 28 days post vaccination. Clotted blood samples were centrifuged ($1,700 \times g$, 15 min) and sera were stored at -20°C until use. None of them had been vaccinated before and did not have neutralizing antibody at the time of immunization. After vaccination any clinical signs appeared after immunization were observed for 28 days.

Serological assay

Virus neutralizing assay (VNA) was determined by the fluorescent antibody virus neutralization (FAVN) test (12). In brief, a positive reference serum of WHO was adjusted to 0.5 IU/ml and used as a positive control. Each serum sample as well as the positive and negative controls were

Statistical analysis

RESULTS

A

Value of IU/ml

Group of raccoon dogs

VacA VacB VacC VacD VacE VacF Con

B

Value of IU/ml

Group of raccoon dogs

VacA VacB VacC VacD VacE VacF Con

raccoon dogs remained sero-negative against rabies at all times. The VN antibody titers of raccoon dogs checked at 28 days post inoculation was higher than those of raccoon dogs at 14 days post inoculation.

All warm blooded animals can be infected by rabid animal's biting and rabid animals show high mortality with various clinical symptoms (13). It is thus essential to inoculate RABV vaccine to animals such as dogs and cattle

raised in rabies risk region. In addition, V-RG bait vaccine has been distributed to block transmission of rabies between wild animals in South Korea. Even though the preventive measure distributing bait vaccine has led to eradication in Gyeonggi-do Province since 2007, the area of rabies occurrence has moved to east northern region of Gangwon-do Province. Even though rabies cases in Korea have been decreased, animal rabies cases have been reported in Gangwon-do Province continually. Although oral vaccinations including V-RG and ONRAB (adenovirus-rabies glycoprotein recombinant oral vaccine) have been used to control rabies of raccoons and skunks in Canada and USA, the proportion of antibody positive raccoons was significantly different between vaccines (14).

Therefore, new strategies such as TVR or PIC program should be prepared to eradicate rabies in the Korean Peninsula. Earlier, it was proved that the TVR program was an effective model to eradicate sylvatic rabies in Ontario State of Canada (15). As the commercial inactivated rabies vaccines are available for dogs and cattle, they need to be demonstrated that the commercial vaccines can induce protective antibody titers in Korean raccoon dogs. To address this, we tested 6 kinds of inactivated rabies vaccines and their immunogenicity in Korean raccoon dogs.

Sobey *et al.*, reported that inoculation of inactivated rabies vaccine by intramuscular route was found to be efficacious in field evaluation of an inactivated vaccine to control raccoon rabies in Canada (16, 11). The kinetics of developing neutralizing antibodies after primary and booster inoculation of rabies vaccine have been studied in pet animals and the second inoculation of rabies vaccine induced more rapid increase and higher levels of circulating antibodies than the primary inoculation (17). Our results also demonstrated that 87.5% (21/24) of raccoon dogs inoculated with 6 kinds of inactivated vaccines developed protective neutralizing antibodies. It is well known that animals with antibody titers >0.5 IU/ml or VN titers $>1:16$ do not develop severe clinical signs of rabies after challenge with virulent rabies virus (16). However, only 25% (1/4) raccoon dogs inoculated with Vaccine A and 50% raccoon dogs with Vaccine B induced VN titer >0.5 IU/ml. Kinetics

of antibody response showed that most of raccoon dogs developed higher VN titer at 28 days post inoculation than at 14 days (Fig. 1). Peak antibody response in pet animals was generally presented in several reports between 4 and 6 weeks after inoculation (18, 19), suggesting that immunogenicity of vaccine A and B need to be evaluated at 6 weeks after application to large number of raccoon dogs. Most of raccoon dogs inoculated with Vaccine A - F showed various geometric mean VN titer ranging from 1.86 to 6.59 IU/ml at 28 days, indicating that each vaccine manufacturer used different kinds of adjuvant, rabies vaccine strain and inactivating agent for the inactivated rabies vaccine. Therefore, if the TVR program is applied to Korean raccoon dogs and is carried out multi-annually, raccoon dogs residing in rabies risk area may have protective neutralizing antibody against rabies. It also reported that raccoon dogs should be revaccinated annually as part of an effective TVR rabies control program (10).

In conclusion, most of commercial inactivated rabies vaccination could induce protective immunity in Korean raccoon dogs and be applicable to new rabies control program. The further study related to immunogenicity of inactivated rabies vaccine in wild animals such as badger will be needed to control rabies in Korea.

REFERENCES

- 1) WHO expert committee on rabies. World Health Organ Tech Rep Ser 1992;824:1-84.
- 2) Joo YS, Lee JH, Lee KK, Bang HA, Lee WC. Retrospective study of extensive vaccination programs for canine rabies control and public health in Korea. *Jpn J Infect Dis* 2011;64:513-5.
- 3) Kim CH, Lee CG, Yoon HC, Nam HM, Park CK, Lee JC, *et al.* Rabies, an emerging disease in Korea. *J Vet Med B Infect Dis Vet Public Health* 2006;53:111-5.
- 4) Yang DK, Kim SY, Oh YI, Lee JA, Cho SD, Lee KW, *et al.* Epidemiological characteristics of rabies in South Korea from January 2004 to March 2011. *J Bacteriol Virol* 2011;41:165-71.
- 5) Johnson N, Black C, Smith J, Un H, McElhinney LM, Aylan O, *et al.* Rabies emergence among foxes in

- Turkey. *J Wildl Dis* 2003;39:262-70.
- 6) Kuzmin IV, Botvinkin AD, McElhinney LM, Smith JS, Orciari LA, Hughes GJ, *et al.* Molecular epidemiology of terrestrial rabies in the former Soviet Union. *J Wildl Dis* 2004;40:617-31.
 - 7) Smith JS, Orciari LA, Yager PA, Seidel HD, Warner CK. Epidemiologic and historical relationships among 87 rabies virus isolates as determined by limited sequence analysis. *J Infect Dis* 1992;166:296-307.
 - 8) Park YJ, Shin MK, Kwon HM. Genetic characterization of rabies virus isolates in Korea. *Virus Genes* 2005;30:341-7.
 - 9) Brown CL, Rupprecht CE. Vaccination of free-ranging Pennsylvania raccoons (*Procyon lotor*) with inactivated rabies vaccine. *J Wildl Dis* 1990;26:253-7.
 - 10) Rosatte RC, Howard DR, Campbell JB, MacInnes CD. Intramuscular vaccination of skunks and raccoons against rabies. *J Wildl Dis* 1990;26:225-30.
 - 11) Sobey KG, Rosatte R, Bachmann P, Buchanan T, Bruce L, Donovan D, *et al.* Field evaluation of an inactivated vaccine to control raccoon rabies in Ontario, Canada. *J Wildl Dis* 2010;46:818-31.
 - 12) Cliquet F, Aubert M, Sagné L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. *J Immunol Methods* 1998;212:79-87.
 - 13) Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, *et al.* *Field virology*. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1221-77.
 - 14) Fehlner-Gardiner C, Rudd R, Donovan D, Slate D, Kempf L, Badcock J. Comparing ONRAB[®] AND RABORAL V-RG[®] oral rabies vaccine field performance in raccoons and striped skunks, New Brunswick, Canada, and Maine, USA. *J Wildl Dis* 2012;48:157-67.
 - 15) Sterner RT, Meltzer MI, Shwiff SA, Slate D. Tactics and economics of wildlife oral rabies vaccination, Canada and the United States. *Emerg Infect Dis* 2009;15:1176-84.
 - 16) Lalosević D, Lalosević V, Lazarević-Ivanc LJ, Knezević I. BHK-21 cell culture rabies vaccine: immunogenicity of a candidate vaccine for humans. *Dev Biol (Basel)* 2008;131:421-9.
 - 17) Aubert MF. Practical significance of rabies antibodies in cats and dogs. *Rev Sci Tech* 1992;11:735-60.
 - 18) Hanlon CA, Niezgoda M, Hamir AN, Schumacher C, Koprowski H, Rupprecht CE. First North American field release of a vaccinia-rabies glycoprotein recombinant virus. *J Wildl Dis* 1998;34:228-39.
 - 19) Minke JM, Bouvet J, Cliquet F, Wasniewski M, Guiot AL, Lemaitre L, *et al.* Comparison of antibody responses after vaccination with two inactivated rabies vaccines. *Vet Microbiol* 2009;133:283-6.